Jackson Thornton Wealth Management LLC Takes Position in Danaher Corporation $DHR

Key Points

• Jackson Thornton Wealth Management LLC acquired 1,775 shares of Danaher Corporation, valued at approximately $356,000, during the second quarter, reflecting growing institutional interest.
• Danaher's stock has a consensus rating of Moderate Buy with a price target of $245.00, as analysts adjust their ratings amid mixed reviews.
• The company recently declared a $0.32 quarterly dividend, with an annualized yield of 0.6%, indicating commitment to returning value to shareholders.

Jackson Thornton Wealth Management LLC acquired a new position in Danaher Corporation (NYSE:DHR - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,775 shares of the conglomerate's stock, valued at approximately $356,000.

A number of other hedge funds have also recently added to or reduced their stakes in DHR. GAMMA Investing LLC increased its holdings in Danaher by 22.2% in the first quarter. GAMMA Investing LLC now owns 9,126 shares of the conglomerate's stock worth $1,871,000 after buying an additional 1,660 shares during the last quarter. Pacific Capital Partners Ltd acquired a new position in Danaher in the first quarter worth approximately $7,175,000. Live Oak Private Wealth LLC increased its holdings in Danaher by 3.9% in the first quarter. Live Oak Private Wealth LLC now owns 45,506 shares of the conglomerate's stock worth $9,329,000 after buying an additional 1,717 shares during the last quarter. Flagship Harbor Advisors LLC increased its holdings in Danaher by 13.7% in the first quarter. Flagship Harbor Advisors LLC now owns 10,149 shares of the conglomerate's stock worth $2,081,000 after buying an additional 1,221 shares during the last quarter. Finally, Sawgrass Asset Management LLC increased its holdings in Danaher by 22.2% in the first quarter. Sawgrass Asset Management LLC now owns 65,643 shares of the conglomerate's stock worth $13,457,000 after buying an additional 11,924 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Rothschild Redb downgraded Danaher from a "strong-buy" rating to a "hold" rating in a report on Wednesday, October 8th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a research report on Friday, July 11th. Wells Fargo & Company decreased their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 23rd. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Finally, Evercore ISI upped their target price on Danaher from $226.00 to $245.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 7th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, Danaher has a consensus rating of "Moderate Buy" and a consensus price target of $245.00.

Insider Buying and Selling at Danaher

In other news, Director Teri List sold 2,778 shares of the stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director directly owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 11.20% of the company's stock.

Danaher Stock Down 0.5%

DHR opened at $208.06 on Tuesday. Danaher Corporation has a 1-year low of $171.00 and a 1-year high of $274.21. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $148.98 billion, a price-to-earnings ratio of 44.27, a P/E/G ratio of 2.98 and a beta of 0.77. The business has a 50 day moving average of $201.76 and a 200-day moving average of $197.42.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the business earned $1.72 earnings per share. Danaher's revenue for the quarter was up 3.4% compared to the same quarter last year. As a group, sell-side analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher's dividend payout ratio is currently 27.23%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.